Non-invasive Vagal Nerve Stimulation for Cognitive and Physical Impairment in Older Adults: A Systematic Scoping Review, Meta-Analysis, and Expert Consultation
Background: Age-related cognitive and physical impairments contribute to loss of independence and healthcare burden. Non-invasive transcutaneous vagus nerve stimulation (tVNS) is a promising non-pharmacological intervention with potential effects across domains relevant to healthy ageing. We synthesised evidence for tVNS in older adults with cognitive or physical impairment and identified priorities for future trials. Methods: Five databases (MEDLINE, Embase, PsycINFO, CINAHL and Web of Science) were searched from inception to 10 March 2026. Primary studies investigating tVNS in older adults with or without cognitive or physical impairment were eligible. Study characteristics, stimulation protocols, outcomes, efficacy, safety and tolerability were synthesised, with random-effects meta-analysis where data were available. Findings were contextualised through consultation with people and carers with lived experience (n=19) and clinicians and researchers (n=12). Findings: Nineteen studies involving 1,159 participants were included, encompassing healthy ageing, cognitive impairment, neurological disease, mobility impairment and cardiometabolic conditions. Most used auricular tVNS, although stimulation protocols and outcome selection varied. No studies evaluated dose–response relationships, and 58 outcome measures were identified. Meta-analyses demonstrated significant effects for studies’ primary outcome(s) (Hedges' g=0·99, 95% CI 0·46–1·53, p0·05). Heterogeneity was substantial, and no study assessed whether benefits persisted. No major adverse effects attributable to tVNS were reported, although safety reporting was inconsistent. Interest-holders prioritised sleep, meaningful functional outcomes, and acceptable home-based delivery. Interpretation: Non-invasive tVNS shows proof-of-concept across outcomes relevant to healthy ageing, with the strongest pooled evidence for mood and sleep. Evidence for sustained cognitive or physical benefit remains insufficient, particularly for cognitive impairment and dementia. Future trials should establish target-specific stimulation protocols, combine clinically meaningful outcomes with mechanistic measures, and incorporate longer follow-up. Convergence between quantitative evidence and interest-holder priorities identified sleep as a promising target for future tVNS trials. Funding This review was funded by the NIHR HealthTech Research Centre Network Challenge Fund (Round 1, 2025). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. SPM is supported by a Canadian Institutes of Health Research (CIHR) Postdoctoral Fellowship Award (AGE-187960) and a Dalhousie University Department of Medicine University Internal Medicine Research Foundation Research Fellowship Award.